-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our target price to $137 from $156, based on 60x our 2027 EPS estimate, a premium to IPGP's historical forward average of ~45x, reflecting the company's transformation toward higher-value applications. We decrease our 2026 EPS estimate to $1.59 from $1.67 and 2027 to $2.29 from $2.40 as management's EPS guidance midpoint came in below consensus and margin headwinds persist. We expect IPGP's strategic pivot to benefit from emerging growth products representing 53% of revenue, strong geographic diversification, and book-to-bill above 1.0. However, we remain cautious given structural margin pressure from tariffs (150-200 bps gross margin drag), Advanced Solutions weakness (-5% Y/Y), and elevated operating expenses. This margin compression, combined with cyclicality risk in battery manufacturing and nascent defense opportunities requiring extended timelines, supports our Hold rating until we see sustained margin recovery and more consistent growth across solution categories.